<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>343</serviceExecutionTime><Drug id="2617"><DrugName>mitumomab</DrugName><DrugNamesKey><Name id="42764349">LuVax</Name><Name id="42764350">MelVax</Name><Name id="42753700">mitumomab</Name></DrugNamesKey><DrugSynonyms><Name><Value>mitumomab</Value><Types><Type>INN</Type></Types></Name><Name><Value>BEC-2</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LuVax</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>MelVax</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>EMD-60205</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>melanoma vaccine, ImClone/Merck KGaA</Value></Name><Name><Value>antimelanoma antibody, ImClone/Merck KGaA</Value></Name><Name><Value>antimetastatic agents, ImClone/Merck KGaA</Value></Name><Name><Value>GD3 ganglioside (vaccine 1), Memorial Sloan-Kettering</Value></Name><Name><Value>IMC-BEC2</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22122">Memorial Sloan-Kettering Cancer Center</CompanyOriginator><CompaniesSecondary><Company id="17193">Imclone LLC</Company><Company id="18101">Merck KGaA</Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2617" type="Drug"><TargetEntity id="223836" type="siDrug">Mitumomab</TargetEntity></SourceEntity><SourceEntity id="17193" type="Company"><TargetEntity id="4295906769" type="organizationId">ImClone LLC</TargetEntity></SourceEntity><SourceEntity id="18101" type="Company"><TargetEntity id="4295869098" type="organizationId">Merck KGaA</TargetEntity></SourceEntity><SourceEntity id="22122" type="Company"><TargetEntity id="4296508772" type="organizationId">Memorial Sloan-Kettering Cancer Center</TargetEntity></SourceEntity><SourceEntity id="1261" type="ciIndication"><TargetEntity id="10041056" type="MEDDRA"></TargetEntity><TargetEntity id="D055752" type="MeSH"></TargetEntity><TargetEntity id="70573" type="ORPHANET"></TargetEntity><TargetEntity id="-1257831198" type="omicsDisease"></TargetEntity><TargetEntity id="614" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1261">Small-cell lung cancer</Indication><Indication id="205">Melanoma</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="211">Anti-idiotype monoclonal antibody</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="280">Immunization passive</Technology><Technology id="596">Injectable formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2017-08-18T08:16:57.000Z</LastModificationDate><ChangeDateLast>2016-09-29T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17193" linkType="Company"&gt;ImClone&lt;/ulink&gt;, under license from &lt;ulink linkID="22122" linkType="Company"&gt;Memorial Sloan Kettering Cancer Center Institute&lt;/ulink&gt;, and licensee &lt;ulink linkID="18101" linkType="Company"&gt;Merck KGaA&lt;/ulink&gt; were developing &lt;ulink linkID="2617" linkType="Drug"&gt;mitumomab&lt;/ulink&gt; (IMC-BEC2, BEC-2, EMD-60205, LuVax, MelVax), an injectable anti-idiotypic monoclonal antibody targeting the tumor antigen GD3, for the potential treatment of small cell lung cancer (SCLC) and malignant melanoma [&lt;ulink linkID="35484" linkType="reference"&gt;35484&lt;/ulink&gt;]. In May 1998, phase III trials for SCLC were initiated [&lt;ulink linkID="287464" linkType="reference"&gt;287464&lt;/ulink&gt;]. In June 2004,  final results were presented showing no difference in progression or survival rates between mitumomab and placebo [&lt;ulink linkID="542114" linkType="Reference"&gt;542114&lt;/ulink&gt;]. Phase II trials for malignant melanoma were initiated in May 2000 [&lt;ulink linkID="367266" linkType="reference"&gt;367266&lt;/ulink&gt;]. However, by July 2004, ImClone and Merck had discontinued development of the agent [&lt;ulink linkID="591970" linkType="Reference"&gt;591970&lt;/ulink&gt;], [&lt;ulink linkID="584333" linkType="Reference"&gt;584333&lt;/ulink&gt;], [&lt;ulink linkID="586192" linkType="Reference"&gt;586192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SMALL CELL LUNG CARCINOMA&lt;/subtitle&gt;A phase III trial was initiated in May 1998. This was planned to involve about 800 patients with small cell lung carcinoma [&lt;ulink linkID="287464" linkType="reference"&gt;287464&lt;/ulink&gt;], [&lt;ulink linkID="307422" linkType="reference"&gt;307422&lt;/ulink&gt;]. Patients who were tumor-free following successful conventional therapy were to be additionally treated with the vaccine to investigate whether it prevents relapses or the subsequent formation of metastases [&lt;ulink linkID="302216" linkType="reference"&gt;302216&lt;/ulink&gt;]. The phase III SILVA study being conducted in the US, Australia, New Zealand and Europe for this indication was continuing at the end of 2000 [&lt;ulink linkID="401203" linkType="reference"&gt;401203&lt;/ulink&gt;]. In April 2001, ImClone reached the halfway mark in enrollment in this trial, triggering a $0.5 million milestone payment from Merck [&lt;ulink linkID="406963" linkType="reference"&gt;406963&lt;/ulink&gt;]. In June 2001, ImClone received another milestone payment of $0.5 million from Merck, triggered by having randomized 50% of the responders into each arm of the trial [&lt;ulink linkID="412913" linkType="reference"&gt;412913&lt;/ulink&gt;]. In January 2002, ImClone stated that it expected enrollment to be completed during 2002 [&lt;ulink linkID="436303" linkType="reference"&gt;436303&lt;/ulink&gt;]. Further data from this trial were presented in June 2004 at the 40th ASCO meeting in New Orleans, LA. A total of 515 patients with limited disease small cell lung cancer were randomized into two groups. The treatment group were administered 8 intradermal injections of &lt;ulink linkID="2617" linkType="Drug"&gt;mitumomab&lt;/ulink&gt; at a dose of 2.5 mg and BCG on weeks, 0, 2, 4, 6 and 10. The most common treatment-related adverse event was a local injection-site reaction and lethargy was noted in 37% of the patients. There were six toxic deaths, four of which were in the 0 mg dose group. To date, 71% of patients have progressed and 72% have died. There was no difference in survival or progression-free survival between the 0 mg/kg and the vaccinated arms [&lt;ulink linkID="542114" linkType="reference"&gt;542114&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;At the 33rd American Society of Clinical Oncology Annual Meeting (May 1997), data were reported from a pilot study in 15 SCLC patients, carried out at the MSKCC, which showed that &lt;ulink linkID="2617" linkType="Drug"&gt;mitumomab&lt;/ulink&gt; significantly increased survival rates [&lt;ulink linkID="271235" linkType="reference"&gt;271235&lt;/ulink&gt;]. The data supported a previous pilot study, completed in May 1996 and also carried out at the MSKCC, which showed that the vaccine improved the overall survival of patients suffering from small cell lung cancer [&lt;ulink linkID="271235" linkType="reference"&gt;271235&lt;/ulink&gt;], [&lt;ulink linkID="325635" linkType="reference"&gt;325635&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;MELANOMA&lt;/subtitle&gt;As of May 2000, clinical trials were ready to commence for those melanoma patients who were disease-free after undergoing surgical resection of deep primary stage II, or stage III or IV disease. The objective of this study was to determine the pharmacological and safety profiles, as well as determine the objective responses of the therapy; patient enrollment in this study has closed. Patient enrollment in another study, involving patients at high risk from melanoma recurrence, was ongoing. Patients in this study were to be vaccinated with both &lt;ulink linkID="2617" linkType="Drug"&gt;mitumomab&lt;/ulink&gt; and BCG and a vaccine construct consisting of GD3-lactone-KLH and QS21, but were to be randomized to determine the order of this combination therapy. The primary goal was to study the ability of these regimens to induce anti-GD3 antibodies [&lt;ulink linkID="367266" linkType="reference"&gt;367266&lt;/ulink&gt;]. These phase II trials were ongoing by January 2002 [&lt;ulink linkID="437833" linkType="reference"&gt;437833&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;&lt;ulink linkID="2617" linkType="Drug"&gt;Mitumomab&lt;/ulink&gt; was designed to mimic GD3, a glycolipid (ganglioside) antigen which is found on the surface of a number of tumor cells, including small cell lung cancer (SCLC), melanoma and a variety of soft tissue sarcomas, and was intended to elicit a cancer-fighting immune response in patients with these tumor cells [&lt;ulink linkID="214456" linkType="reference"&gt;214456&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By 1990, ImClone and &lt;ulink linkID="18101" linkType="Company"&gt;Merck KGaA&lt;/ulink&gt; formed a research and licensing agreement for the development of therapeutic cancer vaccines, including BEC-2, for SCLC and malignant melanoma, which was expanded and modified in May 1996 to include additional licence fees and milestone payments [&lt;ulink linkID="248768" linkType="reference"&gt;248768&lt;/ulink&gt;]. In December 1997, the agreement was modified so that both companies would comarket the product in the US. &lt;ulink linkID="18101" linkType="Company"&gt;Merck KGaA&lt;/ulink&gt; was to continue to hold an exclusive royalty-bearing licence for outside North America [&lt;ulink linkID="271235" linkType="reference"&gt;271235&lt;/ulink&gt;]. However, by July 2004, ImClone and Merck had discontinued development of the agent [&lt;ulink linkID="591970" linkType="Reference"&gt;591970&lt;/ulink&gt;], [&lt;ulink linkID="584333" linkType="Reference"&gt;584333&lt;/ulink&gt;], [&lt;ulink linkID="586192" linkType="Reference"&gt;586192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1996, ImClone was issued US-05529922 covering the vaccine (equivalent patents: WO-09014104, EP-00473721, JP-05500600) [&lt;ulink linkID="214456" linkType="reference"&gt;214456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1998, Merrill Lynch predicted that &lt;ulink linkID="2617" linkType="Drug"&gt;mitumomab&lt;/ulink&gt; would be launched in 2000 [&lt;ulink linkID="300257" linkType="reference"&gt;300257&lt;/ulink&gt;]. In June 1999, Lehman Brothers projected peak sales of $200 million in 2011 [&lt;ulink linkID="329157" linkType="reference"&gt;329157&lt;/ulink&gt;]. In September 2000, Merrill Lynch predicted sales of Eur30 million in 2002, rising to Eur150 million in 2004 [&lt;ulink linkID="383742" linkType="reference"&gt;383742&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-05-20T00:00:00.000Z</StatusDate><Source id="248768" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-05-20T00:00:00.000Z</StatusDate><Source id="248768" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-09T00:00:00.000Z</StatusDate><Source id="401203" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-09T00:00:00.000Z</StatusDate><Source id="401203" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-09T00:00:00.000Z</StatusDate><Source id="401203" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-05-19T00:00:00.000Z</StatusDate><Source id="367266" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-05-20T00:00:00.000Z</StatusDate><Source id="287464" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-09T00:00:00.000Z</StatusDate><Source id="401203" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-09T00:00:00.000Z</StatusDate><Source id="401203" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-09T00:00:00.000Z</StatusDate><Source id="401203" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-05-20T00:00:00.000Z</StatusDate><Source id="287464" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-05-20T00:00:00.000Z</StatusDate><Source id="248768" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-06-01T00:00:00.000Z</StatusDate><Source id="216343" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17810">Eli Lilly &amp; Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18101">Merck KGaA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>2</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="117309" title="ImClone to acquire rights to mitumomab from Memorial Sloan-Kettering Cancer Center "></Deal><Deal id="117314" title="ImClone and Merck KGaA to develop BEC-2-based vaccines against small cell lung carcinoma and malignant melanoma in Australia, New Zeland and Europe"></Deal></Deals><PatentFamilies><PatentFamily id="1240208" number="WO-00038515" title="Peptide mimics useful for treating disease"></PatentFamily><PatentFamily id="1610735" number="WO-09014104" title="Anti-Idiotypic Antibody Which Induces An Immune Response Against A Glycosphingolipid And Use Thereof"></PatentFamily><PatentFamily id="1685169" number="WO-09734635" title="Anti-idiotypic antibody vaccines."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New York University" id="20646"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Memorial Sloan-Kettering Cancer Center" id="22122"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>